[
  {
    "ts": null,
    "headline": "The Cost Of Being Totally Out Of Sync With An AI-Driven Speculative Market",
    "summary": "The Cost Of Being Totally Out Of Sync With An AI-Driven Speculative Market",
    "url": "https://finnhub.io/api/news?id=6e62a2e456da400f7c738565e4933f0a8ac8834daa15a3cebda04eca0df0606b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771971900,
      "headline": "The Cost Of Being Totally Out Of Sync With An AI-Driven Speculative Market",
      "id": 139203669,
      "image": "",
      "related": "CRL",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6e62a2e456da400f7c738565e4933f0a8ac8834daa15a3cebda04eca0df0606b"
    }
  },
  {
    "ts": null,
    "headline": "Baird Maintains Outperform Rating on Charles River Laboratories International, Inc. (CRL)",
    "summary": "Charles River Laboratories International, Inc. (NYSE:CRL) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 20, Mizuho Securities analyst Ann Hynes maintained her Neutral rating on Charles River Laboratories International, Inc. (NYSE:CRL). She reduced the firm’s price target on the stock from $215 to $175. Estimates were […]",
    "url": "https://finnhub.io/api/news?id=6e5306e9f11c77806ffd4d89572cda5f7c4874bb26ae65d933bb2ad83bceb506",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771961929,
      "headline": "Baird Maintains Outperform Rating on Charles River Laboratories International, Inc. (CRL)",
      "id": 139201082,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River Laboratories International, Inc. (NYSE:CRL) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 20, Mizuho Securities analyst Ann Hynes maintained her Neutral rating on Charles River Laboratories International, Inc. (NYSE:CRL). She reduced the firm’s price target on the stock from $215 to $175. Estimates were […]",
      "url": "https://finnhub.io/api/news?id=6e5306e9f11c77806ffd4d89572cda5f7c4874bb26ae65d933bb2ad83bceb506"
    }
  },
  {
    "ts": null,
    "headline": "Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=f222fdfbbd0a685edcaae209c254654b61b237e75039741b10281f704824cc2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771944002,
      "headline": "Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term",
      "id": 139199175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=f222fdfbbd0a685edcaae209c254654b61b237e75039741b10281f704824cc2d"
    }
  }
]